Selected publications
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Gynecologic Oncology.
2016
Review
GET IT
Times cited: 2 -
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Nature Genetics.
2016
Review
GET IT
Times cited: 29 -
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Breast Cancer Research.
2015
Academic Article
GET IT
Times cited: 9 -
Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
2015
Academic Article
GET IT
Times cited: 9 -
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
PLoS Genetics.
2013
Academic Article
GET IT
Times cited: 131 -
Breast cancer risk and 6q22.33: Combined results from breast cancer association consortium and consortium of investigators on modifiers of brca1/2.
PLoS ONE.
2012
Academic Article
GET IT
Times cited: 8 -
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
2012
Academic Article
GET IT
Times cited: 27 -
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Human Molecular Genetics.
2011
Academic Article
GET IT
Times cited: 46